| Poster | Start Time | Abstract Title | Presenter |
|---|---|---|---|
| 15 | 15:35 | Monitoring of Adverse Events in Patients Opioid Users of a Unit of Pain Relief and Palliative Care a Referral Hospital | Carla Ángel Obregón, Santiago, Chile |
| 16 | 15:40 | Management of Adverse Events and Assessment of Adherence in Naïve and Rotation Potent Opioid Patients of Unit Pain Relief and Palliative Care | Prof. Sulamita Miranda Nam, Santiago Chile |
| 11 | 15:45 | Cardiotoxicity Associated with Trastuzumab in Adjuvant Treatment of Early Breast Cancer | Ms.Celia Aparicio Rubio, Alzira, Spain |
| 12 | 15:50 | The Cytoprotective Role of Amifostine in the Re-irradiation of Head and Neck Cancer | Prof. Jens Buentzel, Nordhausen, Germany |
| 17 | 15:55 | Drug Safety Profile Tyrosine Kinase Inhibitors Epidermal Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Used in Patients with Advanced Lung Cancer | Prof. Sulamita Miranda Nam, Santiago, Chile |
| 13 | 16:00 | A Case of Nivolumab-induced Liver Toxicity in Metastatic Lung Cancer | Ms. Wei Liu, Fitzroy, Australia |
| 14 | 16:05 | Cold Agglutinin Disease: A Rare Case Managed with Rituximab | Ms. Wei Liu, Fitzroy, Australia |
| 18 | 16:10 | Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy | Mrs. Cristina Mondelo Garcia, A Coruña, Spain |
| 19 | 16:15 | Pembrolizumab Induced Auto-immune Diabetes and Hepatitis | Ms. Debra Paull, St Leonards, Australia |
| 21 | 16:20 | Physicochemical Stability of Oxaliplatin Beta Infusion Concentrate and Infusion Solutions in Polyolefin Bags Prefilled with 5% Glucose Vehicle Solution Over a 28 Day Period | Dr. Iman Sarakbi, Mainz, Germany |
| 22 | 16:25 | Cost Avoidance, Safety, and Adherence Through Two Week Oral Chemotherapy Clinic Follow-Up | Dr. Sachin Shah, DALLAS, USA |
| 23 | 16:30 | Clinical Pharmacy Service in Children Cancer Centre and Bone Marrow Transplant Unit at a local hospital in Hong Kong | Mr. Kai Him So, Hong Kong, Hong Kong |
| 24 | 16:35 | The Characteristics of Prescription-Related Medication Errors and the Effect of Implementing Chemotherapy Regimen Protocols in Proton and Heavy Ion Radiation Oncology Settings in China | Dr. Bo Yu, Shanghai, China |
| Poster | Start Time | Abstract Title | Presenter |
|---|---|---|---|
| 28 | 15:35 | Diffusion of Innovation in Ambulatory Chemotherapy: Case Study in Lebanon | Miss Racha Sabbagh Dit Hawasli, Surrey, United Kingdom |
| 25 | 15:40 | Developing an Oral Anticancer Drug Disposal Program | Dr. Lisa Holle, Storrs, USA |
| 26 | 15:45 | Standardizing Intrathecal Chemotherapy Preparation & Delivery | Dr. Lisa Holle, Storrs, USA |
| 27 | 15:50 | Assessing the Impact of a National Policy on the Safe Handling of Antineoplastics in Ghana | Miss Asomaniwaa Owusu-Ansah, Accra, Ghana |
| 29 | 15:55 | Prevalence of Poly-pharmacy in the Prostate Cancer Clinic and Patient Interest in a Medicine Review Service | Mr. Joseph Williams, London, United Kingdom |
| 30 | 16:00 | Survey of Chemotherapy Regimen Checks for Oral Anticancer Agents by Pharmacist in the Cancer Designated Hospitals of the NHO/NCC in Japan | Mr. Takahiro Ohta, Kashiwa, Japan |
| Poster | Start Time | Abstract Title | Presenter |
|---|---|---|---|
| 32 | 16:10 | Development of an Algorithm for Risk Assessment and Allocation of Preparation of Monoclonal Antibodies | Dr. Tiene Bauters, Ghent, Belgium |
| Poster | Start Time | Abstract Title | Presenter |
|---|---|---|---|
| 35 | 16:15 | Electronic Simulation for Chemotherapy Checking Training | Ms. Carole Chambers, Calgary, Canada |
| 36 | 16:20 | Investigation in Reduction of Occupational Exposures from Anti-cancer Agents Using the Infusion Set Which Incorporated BD Phaseal™ System | Mr. Toshio Kurihara, Tanabe city Wakayama prefecture, Japan |
| 37 | 16:25 | The Multidisciplinary Approach to Enhance Efficiency in Chemotherapy Day Centre by using Six Sigma Methodology | Mr. Kam Lam, Hong Kong, Hong Kong |
| 38 | 16:30 | Educational Impact and Registrant Perspectives for an Online Fundamental Oncology Pharmacy Conference in Canada | Prof. Tara Leslie, Edmonton, Canada & Dr. John Wiernikowski, Hamilton, Canada |
| 39 | 16:35 | Assessment of a New Closed System Drug-Transfer Device (CSTD) at 13 U.S. Cancer Centers | Dr. Timothy Tyler, Palm Springs, USA |
| Poster | Start Time | Abstract Title | Presenter |
|---|---|---|---|
| 33 | 16:40 | Assessment of Adherence in Patient’s Opioid Users in the Palliative Care Unit | Rodrigo Vega Lepe, Santiago, Chile |
| 34 | 16:45 | Empirical Treatment of Progressive Multifocal Leucoencephalopathy with Mefloquine and Mirtazapine in an Immunocompetent Patient with Multiple Myeloma | Mrs. Josune García de Andoín, San Sebastian, Spain |